------------------------------------------------------------
[link removed]


** New Resources on AVAC.org
------------------------------------------------------------
August 17, 2021

Dear Advocates,

Here’s a roundup of new resources on AVAC.org and PrEPwatch.org!

Vaccine Equity: More must be done now!
* More than 175 leading scientists, civil society leaders and organizations, including AVAC, issued a letter to the White House ([link removed]) on August 10th demanding bold and immediate new steps to scale up mRNA vaccine manufacturing around the world.
* The Washington Post also reported on this effort ([link removed]) to push the Biden Administration to meet key demands, including a commitment to establish the capacity to manufacture 8 billion doses a year of mRNA vaccines before 2022.


CAB-LA and Implementation Science: New options must be paired with smart rollout
* The published results of HPTN’s 083 ([link removed]) study of injectable cabotegravir among cisgender men and transgender women was published on August 12th in the New England Journal of Medicine (NEJM).
* The results were accompanied by an editorial ([link removed]) from CAPRISA ([link removed]) ’s Quarraisha Abdool Karim, stressing the need for implementation science to make sure new PrEP options reach those who need them.
* Find background and context on CAB-LA in AVAC’s Advocates' Primer on Long-Acting Injectable Cabotegravir for PrEP ([link removed]) . And check out a suite of new resources ([link removed]) on PrEPWatch.org ([link removed]) from our Prevention Market Manager project ([link removed]) that draw insights from a decade of experience with oral PrEP programs, with implications for CAB-LA and other next-generation prevention options.


Protecting Global Gains: Resilient health systems look at the whole picture
The latest installment of stories of adaptation among health systems during COVID is up, Flexible programming gives young women in Rwanda the tools they need to get through COVID-19 ([link removed]) . The story showcases one Rwanda program under PEPFAR’s DREAMS program ([link removed]) where the vocational training in tailoring, offered alongside traditional healthcare, gave young women both skills that were needed during the pandemic and critical social support in the midst of lockdown.

The Ethics of Trial Design: Where PrEP fits in for next-generation prevention trials and more
AVAC is taking a long look at two new guidance documents and their implications for HIV prevention trials: The HPTN’s Ethics Guidance for Research ([link removed]) and from UNAIDS/WHO Ethical Considerations in HIV prevention trials ([link removed]) .
* Jeanne Baron’s blog, Ethical Guidance in Focus ([link removed]) , compares the two, including highlights of what’s new from previous guidance documents and a table summarizing the implications.
* AVAC’s August 5th webinar, New Ethical Guidelines for HIV prevention trials in people: What’s changed and Why Does it Matter? ([link removed]) , takes another step in explaining these updated essential documents provide context for their use. Hear advocates and bioethicists discuss the role of PrEP, community engagement, equity and more in future trial design.
* This factsheet ([link removed]) outlines different trial designs under discussion, provides links to background material, and offers details on three trials being designed to test next-generation PrEP: monthly oral PrEP with islatravir from Merck; a new form of daily oral PrEP with F/TAF from Gilead; and six-monthly injectable PrEP with lenacapavir from Gilead.


From IAS 2021
If you are catching up on the 11th annual IAS Conference on HIV Science ([link removed]) , AVAC has the resources you need.
* IAS 2021: Our Take and Updates ([link removed]) rounds up the latest on the prevention pipeline, offers conference highlights on the intersection of COVID-19 and HIV, dives into new findings on PrEP and resistance, looks at how differentiated service delivery (DSD) ([link removed]) has advanced and more.
* Research Literacy Zone Roundup ([link removed]) offers links to sessions where researchers and advocates discuss critical questions for the field, including rollout of the Dapivirine Vaginal Ring, the status of vaccine and cure research, new approaches to address the social determinants of health, vaccine hesitancy and more.


The State of the Field for Rectal Microbicides
AIDS Foundation Chicago (AFC) and AVAC teamed up to host a webinar, Butt Stuff – All Gender HIV Prevention for Backdoor Action ([link removed]) .
* The recorded session ([link removed]) (access passcode: $v62dCvi) features the presentations on the status of research and development for options that focus on the rectum, where HIV infection often occurs.
* The slide presentations are also available as a ([link removed]) PDF.
* And you won’t want to miss the accompanying playlist ([link removed]) , from DJ Taylor Waits ([link removed]) .


The State of the Field for Multi-Purpose Technology
Next up in the AFC and AVAC webinar series, Can Fantasies Become Realities? The Quest for Multi-purpose Prevention Products, is on Wednesday, October 13 10am–12pm EDT. Researcher Dr. Sharon Hillier ([link removed]) and others will discuss the need for products that not only prevent HIV but are contraceptive as well, or prevent other STIs—or all the above. This webinar will also feature performers and a live DJ. Register today! ([link removed])

Best,
AVAC


============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])